Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 254

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Open access
Qin, Jianjun, Xue, Liyan, Hao, Anlin, Guo, Xiaofeng, Jiang, Tao, Ni, Yunfeng, Liu, Shuoyan, Chen, Yujie, Jiang, Hongjing, Zhang, Chen, Kang, Mingqiang, Lin, Jihong, Li, Hecheng, Li, Chengqiang, Tian, Hui, Li, Lin, Fu, Junke, Zhang, Yong, Ma, Jianqun, Wang, Xiaoyuan, Fu, Maoyong, Yang, Hao, Yang, Zhaoyang, Han, Yongtao, Chen, Longqi, Tan, Lijie, Dai, Tianyang, Liao, Yongde, Zhang, Weiguo, Li, Bin, Chen, Qixun, Guo, Shiping, Qi, Yu, Wei, Li, Li, Zhigang, Tian, Ziqiang, Kang, Xiaozheng, Zhang, Ruixiang, Li, Yong, Wang, Zhen, Chen, Xiankai, Hou, Zhiguo, Zheng, Rongrong, Zhu, Wenqing, He, Jie, Li, Yin · 2024 · Nature Medicine

Abstract

Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared to neoadjuvant chemotherapy alone. A total of 391 patients with resectable thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified by clinical stage (I/II, III or IVA) and randomized in a 1:1:1 ratio to undergo two cycles of neoadjuvant therapy. Treatments included camrelizumab, albumin-bound paclitaxel and cisplatin (Cam+nab-TP group; n = 132); camrelizumab, paclitaxel and cisplatin (Cam+TP group; n = 130); and paclitaxel with cisplatin (TP group; n = 129), followed by surgical resection. Both the Cam+nab-TP and Cam+TP groups also received adjuvant camrelizumab. The dual primary endpoints were the rate of pathological complete response (pCR), as evaluated by a blind independent review committee, and event-free survival (EFS), as assessed by investigators. This study reports the final analysis of pCR rates. In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034). The study met its primary endpoint of pCR; however, EFS is not yet mature. The incidence of grade ≥3 treatment-related adverse events during neoadjuvant treatment was 34.1% for the Cam+nab-TP group, 29.2% for the Cam+TP group and 28.8% for the TP group; the postoperative complication rates were 34.2%, 38.8% and 32.0%, respectively. Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC, with a tolerable safety profile. Chinese Clinical Trial Registry identifier: ChiCTR2000040034.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03064-w

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Metadata

Authors
Qin, J., Xue, L., Hao, A., Guo, X., Jiang, T., Ni, Y., Liu, S., Chen, Y., Jiang, H., Zhang, C., Kang, M., Lin, J., Li, H., Li, C., Tian, H., Li, L., Fu, J., Zhang, Y., Ma, J., Wang, X., Fu, M., Yang, H., Yang, Z., Han, Y., Chen, L., Tan, L., Dai, T., Liao, Y., Zhang, W., Li, B., Chen, Q., Guo, S., Qi, Y., Wei, L., Li, Z., Tian, Z., Kang, X., Zhang, R., Li, Y., Wang, Z., Chen, X., Hou, Z., Zheng, R., Zhu, W., He, J., & Li, Y.
Venue
Nature Medicine
Published
2024-07-02
Volume
30
Issue
9
Pages
2549-2557
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4400249061
Cited by
254
References
42
FWCI
97.16
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. https://app.cochat.ai/papers/10.1038/s41591-024-03064-w
The paper
Qin, J., Xue, L., Hao, A., Guo, X., Jiang, T., Ni, Y., Liu, S., Chen, Y., Jiang, H., Zhang, C., Kang, M., Lin, J., Li, H., Li, C., Tian, H., Li, L., Fu, J., Zhang, Y., Ma, J., . . . Li, Y. (2024). Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03064-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.